Tadalafil: A Phosphodiesterase‐5 Inhibitor for Benign Prostatic Hyperplasia
- 25 March 2013
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 33 (6), 639-649
- https://doi.org/10.1002/phar.1243
Abstract
Tadalafil is a phosphodisesterase (PDE)‐5 inhibitor recently approved by the United States Food and Drug Administration for lower urinary tracts symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). The mechanism for improved LUTS is thought to be related to three principal theories: alterations in nitric oxide levels, Rho‐associated protein kinase deactivation, and reductions in pelvic atherosclerosis. The efficacy of PDE‐5 inhibitors for the treatment of LUTS associated with BPH has been demonstrated in several randomized placebo‐controlled trials. Tadalafil is thought to be superior based on an extended half‐life; however, other PDE‐5 inhibitors have positive results in BPH and have not been proved to be inferior to tadalafil. Before administration, concomitant use of medications such as nonselective α‐adrenergic antagonists, nitrates, and cytochrome P450 inhibitors should be assessed for possible drug interactions. Potential adverse drug events seen in Food and Drug Administration–approved tadalafil include back pain, dyspepsia, headache, and dizziness. Given the efficacy and safety data currently available, the PDE‐5 inhibitor tadalafil represents a reasonable alternative for selected male patients with LUTS associated with BPH, especially with concomitant erectile dysfunction.Keywords
This publication has 50 references indexed in Scilit:
- Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo-Controlled, Double-Blind StudyThe Journal of Sexual Medicine, 2012
- Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2011
- Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunctionBritish Journal of Clinical Pharmacology, 2011
- Watchful waiting in benign prostatic hyperplasiaCurrent Opinion in Urology, 2009
- RhoA/Rho kinase‐mediated Ca2+ sensitization in the contraction of human prostateNeurourology and Urodynamics, 2007
- Chronic Treatment with Tadalafil Improves Endothelial Function in Men with Increased Cardiovascular RiskEuropean Urology, 2005
- Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2003
- Benign prostatic hyperplasiaThe Lancet, 2003
- Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic HyperplasiaEuropean Urology, 2000
- Tamsulosin: 3-Year Long-Term Efficacy and Safety in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Analysis of a European, Multinational, Multicenter, Open-Label StudyEuropean Urology, 1999